Arbutus announces presentation of phase 1a/1b clinical trial results for ab-729 in chronic hepatitis b subjects at the liver meeting digital experience™, the american association for the study of liver diseases meeting

Across all single-dose cohorts, mean hbsag concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of ab-729 less frequently than every 4 weeks may be warranted

ABUS Ratings Summary

ABUS Quant Ranking